Evogene (EVGN) has released an update.
Biomica Ltd., an Evogene subsidiary, has reported promising early results in a Phase 1 trial for its microbiome-based cancer therapy, BMC128, used in combination with nivolumab for treating refractory cancers such as NSCLC, melanoma, and RCC. The treatment has shown a favorable safety profile and potential efficacy, with a significant portion of patients experiencing disease stabilization and prolonged response durations. These findings, to be presented at the ASCO 2024 meeting, could herald a new era in personalized cancer care.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
